DHR
Danaher
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 2
consensus rating "Strong Buy"
Bearish Engulfing
High Gross Profit Margin
Revenue Beats Expectation
RSI Oversold
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DHR
Danaher Corporation
A global science and technology innovator that has leadership positions in the demanding and attractive health care, environmental and applied end-markets
Life Science Tools and Services
Invalid Date
12/10/1969
New York Stock Exchange
63000
12-31
Common stock
2200 Pennsylvania Ave. N.W., Suite 800W, Washington, D.C. 20037-1701
Manufacture and sale of life science and diagnostic facilities
Danaher Corporation, originally named DMG, was formed in 1969 as a Massachusetts Caretrust Reit. The company designs, manufactures and sells professional, medical, industrial and commercial products and services that are typically characterized by strong brand names, innovative technologies and dominant market positions. The company's business consists of five parts: test and measurement, environment, life science and diagnosis, dentistry and industrial technology. The company's research and development, manufacturing, sales, distribution, service and management facilities are located in more than 50 countries.
Company Financials
EPS
DHR has released its 2024 Q4 earnings. EPS was reported at 2.14, versus the expected 2.16, missing expectations. The chart below visualizes how DHR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DHR has released its 2024 Q4 earnings report, with revenue of 6.54B, reflecting a YoY change of 2.08%, and net profit of 1.09B, showing a YoY change of 0.65%. The Sankey diagram below clearly presents DHR’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
